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Objectives The objectives of this study were to determine the associations of the metabolic syndrome, inflammatory mark-
ers, and insulin resistance with incident congestive heart failure (CHF), beyond established risk factors, and to
examine whether these risk factors may provide the link between obesity and CHF.
Background Recently, increasing interest has emerged on the potential role of novel risk factors such as systemic inflamma-
tion, insulin resistance, and albuminuria in the pathophysiology of CHF and their relationship with obesity.
Methods The MESA (Multi-Ethnic Study of Atherosclerosis) study is a community-based multicenter cohort study of 6,814
participants (age 45 to 84 years, 3,601 women) of 4 ethnicities: Caucasians, African Americans, Hispanics, and
Chinese Americans. Participants were recruited between 2000 and 2002 from 6 U.S. communities. Median
follow-up time was 4 years. Participants with history of symptomatic cardiovascular disease were excluded. Cox
proportional hazards models were used to analyze the associations of the metabolic syndrome, inflammatory
markers, insulin resistance, and albuminuria with incident CHF, independent of established risk factors (age,
gender, hypertension, diabetes mellitus, left ventricular hypertrophy, obesity, serum total cholesterol, and smok-
ing), an interim myocardial infarction, and baseline magnetic resonance imaging parameters of left ventricular
structure and function.
Results A total of 79 participants developed CHF during follow-up, and 26 participants (32.9%) had a myocardial infarc-
tion prior to CHF and 65% of the cases had CHF with preserved function (left ventricular ejection fraction 40%).
In multivariable analyses, serum interleukin-6 (hazard ratio [HR] for 1 standard deviation 1.50, 95% confidence
interval [CI] 1.10 to 2.03) or C-reactive protein (HR for 1 standard deviation 1.38; 95% CI 1.01 to 1.86) and
macroalbuminuria (HR 4.31, 95% CI 1.58 to 11.76) were predictors of CHF, independent of obesity and the
other established risk factors. Although obesity was significantly associated with incident CHF, this association
was no longer significant after adding inflammatory markers (interleukin-6 or C-reactive protein) to the model.
Conclusions Inflammatory markers and albuminuria are independent predictors of CHF. The association of obesity and CHF
may be related to pathophysiologic pathways associated with inflammation. (J Am Coll Cardiol 2008;51:
1775–83) © 2008 by the American College of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2007.12.048b
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n cardiovascular death rates (5). Although the prophy-
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CHF have been less consistent
in the literature (7–13).
Among the established risk
factors for CHF, obesity merits
special attention, due to the rap-
idly growing obesity pandemic.
Indeed, along with the recent
improvements in the control of
hypertension and hyperlipid-
emia, factors such as obesity and
insulin resistance (IR) are poised
to play a more important role in
the development of cardiovascu-
lar events in the future. Although
obesity is currently considered as
an established determinant of
CHF, the mechanisms by which
it is translated into an increased
risk for CHF remain unclear.
More recently, strong interest
has emerged on novel risk factors
for CHF such as systemic in-
flammation (10,14,15), IR (16–
19), and albuminuria (20,21).
These metabolic risk factors are
recently clustered as part of the
metabolic syndrome, which has
een defined as the concurrence of some or all of abdominal
besity, hypertension, impairment of glucose metabolism,
ipid disturbances, and albuminuria (22,23). The metabolic
yndrome has been associated with LV dysfunction (24),
HF (25), and other cardiovascular events (26,27). Also,
he pro-inflammatory state that characterizes the metabolic
yndrome (28), which is indexed by markers such as
-reactive protein (CRP) (14,29) and interleukin (IL)-6
30,31), may be associated with incident CHF through
athways that do not necessarily include obesity or IR. On
he other hand, diabetes and IR are frequent comorbid
onditions in both obese and nonobese patients with CHF
32). The relative importance of these factors in the general
opulation and their role in the increased risk of CHF that
s associated with obesity are largely unknown. These risk
actors may play a direct role in the increased risk of CHF
ssociated with obesity, or may instead be markers of other
nderlying conditions (18).
We investigated the independent associations of the
etabolic syndrome, inflammatory markers, albuminuria,
nd IR with incident symptomatic CHF beyond obesity and
ther established risk factors for CHF in a multi-ethnic
opulation. We also determined whether these risk factors
redict CHF independent of an interim MI during follow-
p. Finally, we explored whether the associations of obesity
ith incident CHF could be partially explained by these
Abbreviations
and Acronyms
BMI  body mass index
CHF  congestive heart
failure
CI  confidence interval
CPH  Cox proportional
hazards
CRP  C-reactive protein
ECG  electrocardiography
HOMA  homeostasis
model assessment
HR  hazard ratio
IL  interleukin
IR  Insulin resistance
LV  left
ventricle/ventricular
LVEF  left ventricular
ejection fraction
LVH  left ventricular
hypertrophy
MI  myocardial infarction
MRI  magnetic resonance
imaging
UACR  urinary albumin-to-
creatinine ratioovel inflammatory and metabolic risk factors. Sethods
tudy population. The MESA (Multi-Ethnic Study of
therosclerosis) study is a multicenter cohort study of 6,814
en and women (age 45 to 84 years, 3,601 women) who
ave defined themselves as Caucasian (38%), African Amer-
can (28%), Hispanic (22%), or Chinese American (12%).
articipants were recruited between 2000 and 2002 from 6
.S, communities in Maryland, Illinois, North Carolina,
alifornia, New York, and Minnesota. The exclusion cri-
eria included the presence of clinically apparent cardiovas-
ular disease at baseline. The design of the MESA study has
een described in detail elsewhere (33). The study was
pproved by the institutional review boards at all participat-
ng centers and all participants gave informed consent.
aseline examination. Standardized questionnaires were
sed to obtain information about smoking and medication use
34). Body mass index (BMI) was calculated as BMI weight
kg)/ height2 (m2) from weight measured to the nearest 0.5 kg
nd height to the nearest 0.1 cm. Obesity and overweight were
efined as BMI 30 kg/m2 and 25  BMI 30 kg/m2,
espectively. Hypertension was defined as systolic blood pres-
ure 140 mm Hg and/or diastolic blood pressure 90 mm
g and/or use of antihypertensive medications. Diabetes was
efined as fasting glucose126 mg/dl or use of hypoglycemic
edication.
Fasting plasma glucose and insulin levels were measured
t baseline. Insulin levels were determined by a radioimmu-
oassay method using the Linco Human Insulin Specific
IA Kit (Linco Research, Inc., St. Charles, Missouri). As
n index of IR, homeostasis model assessment (HOMA)
ndex was calculated using the formula HOMA  (fasting
lucose [mmol/l])(fasting insulin [U/ml)])/22.5 (35). Uri-
ary creatinine and albumin were measured using the Vitros
50IRC instrument (Johnson & Johnson Clinical Diagnos-
ics, Inc., Rochester, New York) and the Array 360 CE
rotein Analyzer (Beckman Instruments, Inc., Fullerton,
alifornia), respectively. Participants were categorized into
groups based on baseline urinary albumin (mg)/creatinine
g) ratio (UACR): 1) normal: UACR 30; 2) microalbu-
inuria: UACR 30 to 300; and 3) macroalbuminuria:
ACR 300 (36).
The metabolic syndrome was defined using the Adult
reatment Panel III criteria (22). Participants with 3 or
ore of these criteria were considered as having metabolic
yndrome: abdominal obesity, given as waist circumference
102 cm in men and 88 cm in women); serum triglyc-
rides 150 mg/dl; high-density lipoprotein cholesterol
40 mg/dl in men and 50 mg/dl in women; blood
ressure 130/85 mm Hg or use of antihypertensive
edications; fasting glucose 110 mg/dl or use of hypo-
lycemic medications. Serum levels of IL-6, CRP, and
brinogen were measured as markers of systemic inflamma-
ion. Levels of IL-6 were determined by ultrasensitive
LISA (Quantikine HS Human IL-6 Immunoassay, R&D
ystems, Minneapolis, Minnesota), and CRP levels were
m
C
n
B
b
p
M
d
d
c
F
t
r
i
e
a
M
o
a
T
p
p
p
a
2
p
f
C
w
a
S
d
c
i
f
r
b
d
(
s
a
T
a
C
L
c
r
E
t
c
o
M
i
i
n
e
m
h
i
p
M
M
d
p
b
w
p
s
f
w
c
r
t
u
c
w
t
a
s
c
v
a
o
f
s
m
c
r
i
r
v
T
R
S
C
p
l
a
i
p
(
T
d
p
1777JACC Vol. 51, No. 18, 2008 Bahrami et al.
May 6, 2008:1775–83 Metabolic Risk Factors, Obesity, and Incident CHFeasured by the BNII nephelometer (N High Sensitivity
RP, Dade Behring Inc., Deerfield, Illinois). The BNII
ephelometer (N Antiserum to Human Fibrinogen; Dade
ehring Inc.) was used to determine fibrinogen.
Left ventricular structure and function were determined
y magnetic resonance imaging (MRI) at baseline in 5,004
articipants (73.4%) who agreed to undergo MRI. The
RI protocol and analysis methods have been previously
escribed (37). In addition to LV mass measured by MRI,
ata regarding LVH in electrocardiography (ECG) were
ollected in all participants.
ollow-up and outcome parameter. Median follow-up
ime was 4.0 years (interquartile range: 3.1 to 4.2 years),
esulting in 25,107 person-years of observation. A telephone
nterviewer contacted each participant (or representative)
very 6 to 9 months to inquire about all interim hospital
dmissions, cardiovascular outpatient diagnoses, and deaths.
edical records and information were successfully obtained
n an estimated 98% of hospitalized cardiovascular events
nd 95% of outpatient cardiovascular diagnostic encounters.
wo physicians reviewed all records for independent end
oint classification and assignment of event dates.
The end point for this study was symptomatic CHF. End
oint criteria included symptomatic CHF diagnosed by a
hysician and patient receiving medical treatment for CHF
nd 1) pulmonary edema/congestion by chest X-ray, and/or
) dilated ventricle or poor LV function by echocardiogra-
hy or ventriculography, or evidence of LV diastolic dys-
unction. Participants who had a physician’s diagnosis of
HF were classified as having CHF. Myocardial infarction
as diagnosed based on combinations of symptoms, ECG,
nd cardiac biomarker levels.
tatistical methods. Data are presented as mean  stan-
ard deviation (SD) or median (interquartile range) for
ontinuous variables and number (percentage) for categor-
cal variables. Logarithmic transformation was performed
or serum insulin, HOMA index, serum IL-6, and CRP to
educe the skewness in the distributions. Differences in
aseline characteristics of participants who developed and
id not develop CHF were tested with Student t test
continuous variables with normal distribution) or chi-
quare test (categorical variables).
Cox proportional hazards (CPH) models were used to
nalyze the association of risk factors with incident CHF.
hree sets of models were used: Model 1: unadjusted
nalysis; Model 2: adjusted for established risk factors of
HF, which include age, gender, hypertension, diabetes,
VH in ECG, obesity, serum total cholesterol, and current
igarette smoking; and Model 3: adjusted for the established
isk factors included in Model 2 plus baseline LV function.
ach novel risk factor was included in a separate model with
he established risk factors in Models 2 and 3. Due to
ollinearity between different parameters of LV function, we
nly included left ventricular ejection fraction (LVEF) in
odel 3, because LVEF had the strongest association withncident CHF (highest hazard ratio [HR] for 1 SD change pn the predictor) in univariable analysis. The most parsimo-
ious models were defined using a stepwise backward
limination in which age and gender were retained in the
odels and elimination was based on p values and likeli-
ood ratio test.
To evaluate whether these risk factors predicted CHF
ndependent of an interim MI during the follow-up, we
erformed an additional analysis in which we added interim
I as a time-varying covariate to Model 3. Using interim
I as a time-varying covariate allowed participants who
eveloped CHF following an interim MI to contribute to
erson-times at risk for “CHF without prior interim MI”
efore they had MI and to person-times at risk for “CHF
ith prior interim MI” after they experienced MI. We also
erformed 2 ancillary analyses: 1) multivariable analysis in a
ubsample without participants with interim MI during
ollow-up, and 2) CPH model analyses in which patients
ith interim MI were censored at the time of MI diagnosis.
Results of CPH models are reported as HRs and 95%
onfidence intervals (CIs). All HRs are calculated and
eported for 1 SD increase in continuous variables or
ransfer from 1 level to another of categorical variables,
nless stated otherwise. Proportionality of hazards was
hecked by visually examining “log-log” plots. Participants
ho were lost to follow-up (11%) were censored at the
ime of the last follow-up. To evaluate how much of the
ssociation of obesity with incident CHF was related to
ystemic inflammation and IR, we compared the regression
oefficient for obesity before and after adjusting for these
ariables. Missing values were handled based on our a priori
nalysis plan, that is, only participants who had missing data
n a variable needed for a particular model were excluded
rom the analysis. This method was used to maximize the
tatistical power, and in view of the negligible percentage of
issing data to control for intercenter variability, study
enter was included as a categorical variable in the multiva-
iable models. Cumulative hazards of CHF were illustrated
n Nelson-Aalen plots and were compared using the log-
ank test. Statistical analyses were performed using Stata
ersion 8.2 for Windows (StataCorp, College Station,
exas).
esults
eventy-nine out of 6,814 MESA participants developed
HF during follow-up (incidence rate: 3.1 per 1,000
erson-years). Participants who developed CHF were more
ikely to be older, male, obese, current smoker, hypertensive,
nd diabetic (Table 1). Although the absolute risk of CHF
n nonobese participants was 10 per 1,000, obese partici-
ants had a risk of 16 per 1,000 for developing CHF
attributable risk: 6 per 1,000; 95% CI 0.0004 to 0.012).
he attributable risks associated with hypertension and
iabetes were 11 per 1,000 (95% CI 0.006 to 0.017) and 19
er 1,000 (95% CI 0.008 to 0.030), respectively. Of the 79
articipants who developed CHF during follow-up, 26
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Metabolic Risk Factors, Obesity, and Incident CHF May 6, 2008:1775–8332.9%) had an interim MI, and 3 (3.8%) participants had a
linical MI after being diagnosed as CHF.
etabolic syndrome, insulin resistance, and inflamma-
ory markers. The metabolic syndrome was observed in
,362 participants (34.7%) at baseline. In unadjusted mod-
ls, participants who met Adult Treatment Panel III criteria
or the metabolic syndrome at baseline were at higher risk of
eveloping CHF (HR 2.04). The absolute risks of CHF
ere 17 per 1,000 and 9 per 1,000 in participants with and
ithout the metabolic syndrome, respectively (attributable
isk 9 per 1,000; 95% CI 0.003 to 0.015). Among the 5
riteria used in the definition of the metabolic syndrome,
erum triglyceride and high-density lipoprotein cholesterol
ere not significant predictors of incident CHF.
Markers of systemic inflammation were significant pre-
ictors of CHF. Among these markers, IL-6 was the
trongest predictor in the unadjusted models (HR of 1.84
or each SD increase in log serum IL-6). The absolute risks
istribution of Baselineharacteristics of the MESA Participants by Gender*
Table 1 Distribution of BaselineCharacteristics of the MESA Participants by Gender*
Characteristic
Men
(N  3,213)
Women
(N  3,601)
Demographic and anthropometric
characteristics
Age, yrs 62.2  0.2 68.3  1.2
Ethnicity, n (%)
African Americans 1,261 (39.2) 1,363 (37.8)
Hispanics 718 (22.4) 774 (21.5)
Caucasians 844 (26.3) 1,051 (29.2)
Chinese Americans 390 (12.1) 413 (11.5)
Body mass index, kg/m2 27.9  0.1 28.8  0.1
Waist circumference, cm 99.3  0.2 97.1  0.3
Established risk factors for CHF
Obesity 903 (28.1) 1,294 (35.9)
Overweight 1,447 (45.0) 1,217 (33.8)
Cigarette smoking, n (%)
Never 1,301 (40.7) 2,125 (59.3)
Former 1,427 (44.7) 1,037 (29.0)
Current 465 (14.6) 420 (11.7)
Diabetes classification, n (%)
Normal 1,645 (51.4) 2,281 (63.6)
IFG† 1,055 (32.9) 840 (23.4)
Diabetes 503 (15.7) 466 (13.0)
Hypertension, n (%) 1,497 (46.6) 1,754 (48.7)
Mean arterial pressure (mm Hg)‡ 92.0  0.2 88.4  0.2
Diastolic blood pressure (mm Hg) 75.0  0.2 69.1  0.2
LVH in electrocardiography, n (%) 46 (1.4) 22 (0.6)
LV mass index (g) 85.8  0.3 70.8  0.2
Metabolic syndrome 994 (30.1) 1,338 (38.0)
Incident symptomatic CHF 52 (1.6) 27 (0.8)
Myocardial infarction during follow-up, n (%) 59 (1.8) 19 (0.5)
or continuous variables, mean values  standard errors are shown. Percentages for continuous
ariables are shown in parentheses. *All participants with symptomatic CHF or any other kind of
ardiovascular disease at baseline were excluded from the study. †IFG was defined as fasting
lucose 100 to 125 mg/dl. ‡Mean arterial pressure  2/3  diastolic blood pressure  1/3 
ystolic blood pressure
CHF  congestive heart failure; IFG  impaired fasting glucose; LV  left ventricle; LVH  left
entricular hypertrophy; MESA  Multi-Ethnic Study of Atherosclerosis.or CHF were 21 per 1,000 among participants at top Muartile of serum IL-6 and 8 per 1,000 among those in the
ower three quartiles (attributable risk: 13 per 1,000; 95% CI
.005 to 0.20). A serum CRP 5 mg/dl was also signifi-
antly associated with an 87% increase in the risk of CHF
HR 1.87; 95% CI 1.16 to 3.00) and an increase in absolute
isk from 10 per 1,000 to 18 per 1,000 (attributable risk: 8
er 1,000; 95% CI 0.001 to 0.016). Figure 1 illustrates the
umulative hazard of CHF by metabolic risk factors.
Higher fasting glucose levels were associated with a high
isk of incident CHF. Participants with a HOMA score
95th percentile (4.8 U) were at a marginally higher risk of
HF compared to those with HOMA scores 95th per-
entile (HR 2.00, p  0.06). On the other hand, both
acroalbuminuria (UACR 300) and microalbuminuria
UACR: 30 to 300) were significant predictors of CHF
HR 9.47 and 4.40, respectively). The absolute risk for
HF increased from 8 per 1,000 in participants with
ormal UACR to 38 and 79 per 1,000 in those with micro-
nd macroalbuminuria, respectively.
aseline LV structure and function and incident CHF.
ecause MESA participants had no history of heart disease
t baseline, the frequencies of individuals with abnormal LV
tructure and function were likely to be less than in the
eneral population. In this regard, 98.7% of MESA partic-
pants had LVEF50%, and this proportion was 84.8% (67
articipants) among the 79 participants who developed
HF. On the other hand, among the 6,814 participants of
ESA, 505 participants (10.1%) would be considered to
ave LVH by Framingham criteria, and among participants
ho developed CHF, 17 participants (32.1%) had LVH at
aseline. As shown in Table 2, LVEF, LV mass index, LV
nd-diastolic volume, LV end-systolic volume, and LV
ass to end-diastolic volume ratio at baseline were all
ignificant predictors of incident CHF. Among different
arameters of LV function, LVEF had the strongest inde-
endent association with incident CHF, and therefore, we
sed LVEF as a covariate in multivariable CPH models
Table 2, column 3). Moreover, among 60 cases for which
ata on LV function at the time of CHF diagnosis were
vailable, 52 patients (87%) had LVEF 30%, 39 partici-
ants (65%) had LVEF 40%, and 33 participants (55%)
ad LVEF 50%.
djustment for established risk factors and baseline LV
tructure and function. The results of the multivariable
PH models are shown in Table 3. Serum levels of IL-6,
RP, and fibrinogen as well as presence of microalbumin-
ria and/or macroalbuminuria were significant predictors of
HF, independent of established risk factors and LV
unction at baseline. The metabolic syndrome and HOMA
ndex were not significantly associated with CHF in Models
and 3, after adjustment for established risk factors and LV
unction. Among the different metabolic syndrome criteria,
lasma glucose and abdominal obesity were the strongest
redictors of incident CHF (Table 3). Note that lack of
ssociation between CHF and high blood pressure inodels 2 and 3 is probably due to inclusion of LVH, which
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inuria, included in the World Health Organization crite-
ia for the metabolic syndrome (23), was also a significant
redictor.
Although obesity was a significant predictor of CHF,
dding inflammatory markers (IL-6 or CRP) to any of
he CHP models, which included obesity (or BMI),
esulted in a considerable reduction in the magnitude of
he association between obesity and incident CHF, and
Figure 1 Cumulative Hazards of CHF by Categories of Inflamma
Nelson-Aalen plots of cumulative hazards for congestive heart failure (CHF) in the
of interleukin (IL)-6, C-reactive protein (CRP), metabolic syndrome, and albuminuria
Unadjusted and Adjusted Hazard Ratios of CHFMRI-Defined LV Structure and Function at Basel
Table 2 Unadjusted and Adjusted Hazard RaMRI-Defined LV Structure and Func
Parameters of LV Structure and Function
LVEF (per 7.4% decrement)
LVEF 50%
End-diastolic volume index‡ (per 13.6 ml/m2)
End-systolic volume index‡ (per 8.1 ml/m2)
Stroke volume index‡ (per 9.0 ml/m2)
LV mass index‡ (per 16.3 g/m2)
LV mass/volume ratio (per 0.25 g/ml)
*Hazard ratios are calculated for 1 standard deviation increase in con
†Age, gender, hypertension, diabetes mellitus, LV hypertrophy, obesity
LV mass were indexed to body surface area.
MRI  magnetic resonance index; other abbreviations as in Table 1.his association was no longer significant. For example,
hen IL-6 or CRP were added to the univariable
nalyses, the HR for obesity changed from 1.65 (p 
.03) to 1.16 (p  0.53) and 1.38 (p  0.18), respec-
ively. Similarly, the HR associated with obesity in
odel 2 changed from 1.83 (p  0.01) to 1.50 (p  0.11)
nd 1.58 (p  0.06), respectively, when IL-6 and CRP
ere added to Model 2. Substitution of obesity for BMI
s a continuous variable yielded similar results.
Markers, Metabolic Syndrome, and Albuminuria
(Multi-Ethnic Study of Atherosclerosis) study by categories
75th percentiles for IL-6 and CRP were 1.9 and 4.3 mg/dl, respectively.
lation tothe MESA Study (N  5,004)
of CHF in Relation to
t Baseline in the MESA Study (N  5,004)
Hazard Ratios (95% Confidence Interval)*
Unadjusted
Adjusted for Established
Risk Factors†
.89 (1.49–2.27) 1.69 (1.37–2.08)
.92 (7.88–28.26) 8.30 (4.26–16.17)
.76 (1.46–2.13) 1.71 (1.40–2.08)
.71 (1.53–1.90) 1.63 (1.44–1.87)
.98 (0.74–1.29) 1.11 (0.86–1.44)
.87 (1.67–2.09) 1.84 (1.56–2.18)
.64 (1.39–1.96) 1.21 (0.96-1.51)
variables or transfer from 1 level to another of categorical variables.
cholesterol, and current cigarette smoking. ‡Absolute volumes andtory
MESA
. Thein Rei e in
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Metabolic Risk Factors, Obesity, and Incident CHF May 6, 2008:1775–83I during follow-up and the association of obesity with
ncident CHF. Interim MI during follow-up was associated
ith a significant increase in the risk of CHF (HR 112.24;
5% CI 69.20 to 182.03). Even though CRP remained
ssociated with CHF (HR 1.42; 95% CI 1.05 to 1.92) after
dding interim MI to Model 3 (including established risk
actors and LV function), the metabolic syndrome and obesity
ere no longer significant predictors. However, in the model
ncluding interim MI, microalbuminuria remained associated
ith incident CHF (HR 2.40; 95% CI 1.13 to 5.08).
When the analyses were limited to the subsample of
articipants without interim MI, obesity, inflammatory
arkers, metabolic syndrome, and macroalbuminuria were
ignificantly associated with incident CHF. Using Model 3
adjusted for baseline LV function) in the subpopulation
nadjusted and Adjusted Hazard Ratios for Symptomatic CHFn Relation to Novel M tabolic Risk Fact s in the MESA Study (n
Table 3 Unadjusted and Adjusted Hazard Ratios for Symptomatin Relation to Novel Metabolic Risk Factors in the ME
Characteristic† Model 1: Unadjus
Established risk factors
Age 1.97 (1.55–2.50
Male gender 2.16 (1.35–3.44
Obesity (BMI 30 kg/m2) 1.65 (1.05–2.57
Diabetes mellitus 3.17 (1.98–5.08
Hypertension 2.88 (1.76–4.72
LVH in electrocardiography 14.23 (7.09–28.5
Current smoking (vs. never smoking) 1.85 (1.0–3.41)
Serum cholesterol (per 35.7 mg/dl) 1.01 (0.80–1.26
Metabolic syndrome
Metabolic syndrome 2.04 (1.31–3.17
Abdominal obesity¶ 1.82 (1.13–2.93
High plasma glucose (110 mg/dl) 3.24 (2.07–5.05
High blood pressure (130/85 mm Hg) 2.66 (1.57–4.50
Low serum HDL cholesterol** 0.94 (0.59–1.50
High serum triglycerides (150 mg/dl) 1.11 (0.69–1.78
Glucometabolic factors
Fasting plasma glucose (per 30.9 mg/dl) 1.28 (1.13–1.45
Fasting plasma insulin (per 0.64 log U/ml) 0.96 (0.77–1.20
HOMA insulin resistance index (per 0.73 log unit) 1.14 (0.85–1.54
HOMA insulin resistance index 95th percentile 2.00 (0.96–4.15
UACR
Normal (UACR 30) 1.0 (reference)
Microalbuminuria (UACR: 30 to 300) 4.40 (2.59–7.46
Macroalbuminuria (UACR 300) 9.47 (4.28–20.9
Markers of systemic inflammation
Interleukin 6 (per 0.66 log pg/ml) 1.84 (1.48–2.28
CRP (per 1.16 log mg/dl) 1.36 (1.09–1.70
Serum fibrinogen (per 73.9 mg/dl) 1.37 (1.14–1.66
Hazard ratios are calculated for 1 standard deviation increase in continuous variables or transfer
t a time, that is, each model included 1 novel risk factor plus established risk factors for Model 2
besity, serum cholesterol, and current cigarette smoking. Values for established risk factors are
etermined by MRI at baseline was used as a parameter of LV function. Defined as the presence
nd88 cm in women. #In Models 2 and 3 for high blood glucose and high blood pressure (as 2 c
s independent variables (due to high correlations with the dependent variables). However, using
holesterol 40 mg/dl in men and 50 mg/dl in women.
BMI body mass index; CRP C-reactive protein; HDL high-density lipoprotein; HOMA hom
and 2.ithout interim MI, age, CRP, obesity, serum cholesterol, sVEF, current or former smoking, and LVH were signif-
cant predictors of CHF.
Finally, in another set of ancillary analyses, the patients
ith interim MI were censored (at the time of diagnosis of
I). The results of univariable analyses (Model 1) as well as
odels 2 and 3 in these sets of models were similar to the
esults of the analysis in which interim MI was treated as a
ime-varying covariate. However, the magnitude of the
ssociation between obesity and CHF was higher in Model
(HR 2.7; 95% CI 1.6 to 4.7). Novel risk factors signifi-
antly associated with CHF in univariable analyses included
he metabolic syndrome, macroalbuminuria, microalbumin-
ria, IL-6, CRP, and fibrinogen. Using Model 3 in this set
f analyses, serum CRP, age, gender, obesity, cigarette
moking, serum cholesterol, LVH, and baseline LVEF were
14)
F
udy (n  6,814)
Hazard Ratios (95% Confidence Interval)*
Model 2: Adjusted for
Established Risk Factors‡
Model 3: Adjusted for
Established Risk Factors and
LV Function at Baseline§
1.96 (1.50–2.56) 2.07 (1.49–2.89)
2.09 (1.27–3.42) 1.92 (0.99–3.69)
1.83 (1.14–2.92) 1.58 (0.87–2.87)
2.06 (1.25–3.39) 1.99 (1.08–3.68)
1.49 (0.87–2.54) 1.69 (0.88–3.25)
8.38 (4.05–17.31) 6.91 (2.93–16.29)
2.74 (1.45–5.17) 3.91 (1.80–8.52)
1.21 (0.97–1.50) 1.45 (1.13–1.87)
1.08 (0.63–1.86) 1.60 (0.89–2.87)
2.06 (1.25–3.41) 1.73 (0.97–3.08)
2.30 (1.45–3.64)# 3.06 (1.74–5.37)¶
1.32 (0.75–2.33)# 1.54 (0.79–3.02)#
0.79 (0.49–1.29) 0.95 (0.53–1.70)
0.97 (0.58–1.57) 1.11 (0.61–2.00)
1.20 (1.04–1.38) 1.31 (1.12–1.54)
0.75 (0.58–0.96) 0.78 (0.57–1.07)
0.74 (0.57–0.98) 0.80 (0.58–1.10)
1.30 (0.59–2.88) 1.30 (0.43–3.93)
1.0 (reference) 1.0 (reference)
2.73 (1.56–4.78) 1.80 (0.83–3.86)
5.27 (2.30–12.11) 4.81 (1.76–13.10)
1.64 (1.31–2.06) 1.44 (1.09–1.92)
1.35 (1.06–1.73) 1.41 (1.06–1.87)
1.25 (1.02–1.53) 1.26 (0.99–1.61)
level to another of categorical variables. †Novel risk factors were included in Models 2 and 3 one
stablished risk factors and LVEF for Model 3. ‡Age, gender, hypertension, diabetes mellitus, LVH,
he multivariable model including only established risk factors. §Left ventricular ejection fraction
more of the 5 criteria for the metabolic syndrome (22). ¶Waist circumference 102 cm in men
or metabolic syndrome), we did not include the variables diabetes and hypertension, respectively,
ations for diabetes and hypertension were included in these models. **High-density lipoprotein
s model assessment; UACR urinary albumin-to-creatinine ratio; other abbreviations as in Tables 6,8
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his study reports on the associations of obesity and the
etabolic syndrome with incident CHF in a multi-ethnic
opulation in which baseline LV structure and function
ere carefully assessed by MRI. We demonstrate strong
ssociations of inflammatory components of the metabolic
yndrome and albuminuria with incident CHF, even after
djustment for established risk factors, LV dysfunction, and
nterim MI. Moreover, the results indicate that inflamma-
ion may play an important role in the association between
besity and incident CHF.
Even though the metabolic syndrome represents a con-
tellation of several risk factors for cardiovascular disease,
his constellation has been recognized as a risk factor for
ardiovascular morbidity and mortality (25–27). However,
here are only a few previous studies that have specifically
valuated the association of the metabolic syndrome with
ncident CHF and whether the concurrence of these specific
actors puts any given individual at a risk beyond what is
xpected based on the known associations of each risk factor
ith CHF. Our results show that although the metabolic
yndrome is strongly associated with incident CHF, this
ssociation is largely explained by its specific risk factor
omponents. Also, among the 5 criteria that are used for the
iagnosis of the metabolic syndrome, high levels of plasma
lucose, abdominal obesity, and hypertension were the
trongest predictors of incident CHF.
besity, inflammation, and incident CHF. This study
xtends our knowledge of the association between systemic
nflammation and CHF by showing that this strong asso-
iation is independent of both interim MI during follow-up
nd baseline LV systolic function measured by MRI. Also,
ur results suggest that inflammation might be involved,
irectly or as a marker of other underlying conditions, in the
athologic pathways that link obesity to LV dysfunction and
ltimately CHF. Previous studies have shown that IL-6,
L-2, CRP, and tumor necrosis factor-alpha are associated
ith CHF (14,38,39) and subclinical LV dysfunction (40–
2). Experimental studies have also shown that IL-6 and
umor necrosis factor-alpha are associated with progressive
V dysfunction, LV remodeling, myocyte hypertrophy, and
yocyte apoptosis (43–45). Some mechanisms suggested
or these associations include immune activation, myocar-
ial biosynthesis of inflammatory markers, underperfusion
f systemic tissues, absorption of endotoxins from the
dematous intestines, and neurohormonal activation/
tabilization (43). However, it remains unclear whether the
ssociation between inflammatory markers and CHF is
ausal or indirectly related to other local or generalized
nflammatory states.
Obesity was an independent risk factor for CHF in our
tudy. However, obesity was not significantly associated
ith CHF after adjustment for baseline LV systolic func-
ion or for inflammatory markers. These findings suggest
hat the association of obesity with CHF is mediated by LV dystolic dysfunction and might be at least in part explained
y pathways related to inflammation. Inflammation, on the
ther hand, could theoretically be linked to incident CHF
hrough pathways related to, or independent of, LV systolic
ysfunction.
mpaired glucose metabolism, albuminuria, and incident
HF. In the MESA community-based population, al-
hough high fasting glucose was a significant predictor of
HF, the association of high HOMA index (above 95th
ercentile) with CHF was only marginally significant in
nivariable analysis and not significant in multivariable
nalysis. These results are different from those of a previous
tudy (18) of 1,187 Swedish men in which the HOMA
ndex was an independent risk factor for CHF. Another
actor that is closely related to impaired metabolism of
lucose (46) is albuminuria; our study shows that both
icro- and macroalbuminuria are strong predictors of
HF. In previous studies, we have documented that pro-
ressive regional myocardial systolic or diastolic dysfunction
s associated with renal dysfunction in a subset of MESA
articipants (21). The association of albuminuria with CHF
as been previously demonstrated in the HOPE (Heart
utcomes Preventive Evaluation) study (20). Albuminuria
s considered as a marker of microvascular and macrovascu-
ar disease (47), and it has been associated with several
ardiovascular risk factors and inflammatory markers
44,48).
trengths and limitations. The strengths of this study
nclude the large ethnically diverse population, detailed
linical and metabolic characterization of the cohort, and
recise measurements of LV structure and function by
RI. There are, however, some limitations to this study.
ecause inflammatory markers and obesity were measured
t the same time, the conclusions regarding the possible
echanistic role of systemic inflammation in the association
f obesity with CHF should be interpreted cautiously.
urther specific studies are required for additional insights
nto this pathophysiologic link. Moreover, the median
ollow-up time was 4 years, and considering the low
ncidence of CHF, a longer follow-up duration could have
ncreased the study’s statistical power. Conversely, however,
he fact that the associations of the novel risk factors, for
xample, inflammatory factors and albuminuria, with CHF
ere significant during this relatively short period might
lso reflect the strength of these associations. Our study had
4% power to detect a HR of 1.5 associated with the
resence of a risk factor in 10% of the population. The
ower was lower for multivariable as opposed to univariable
odels and higher for risk factors with prevalence rates
reater than 10% and for continuous variables.
onclusions
nflammatory markers and albuminuria are independent
redictors of CHF beyond traditional risk factors and the
evelopment of an interim clinical MI. The presence of the
m
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Metabolic Risk Factors, Obesity, and Incident CHF May 6, 2008:1775–83etabolic syndrome is associated with a higher risk for
HF, and this association is mainly related to impaired
lucose metabolism, hypertension, abdominal obesity, and
he pro-inflammatory state that characterizes the metabolic
yndrome. The association of obesity and CHF may be
elated to pathophysiologic pathways associated with in-
ammation. Further studies are needed to elucidate the
mportance of these novel risk factors in the prophylaxis of
rogressive LV dysfunction and CHF.
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PPENDIX
full list of participating MESA investigators and institu-
ions can be found at http://www.mesa-nhlbi.org.
